Skip to main content

Advertisement

Advertisement

commentary Commentary

Commentary: Why rushing a COVID-19 vaccine could spell disaster

Countries are considering bypassing phases of testing in order to quicken the process of obtaining a vaccine, says an observer.

Commentary: Why rushing a COVID-19 vaccine could spell disaster

FILE PHOTO: Alexander Gintsburg, director of the Gamaleya National Research Center for Epidemiology and Microbiology, shows bottles with Sputnik-V vaccine against the coronavirus disease (COVID-19) during an interview with Reuters in Moscow, Russia September 24, 2020. REUTERS/Tatyana Makeyeva

SINGAPORE: With COVID-19 cases still rising globally, the race is on for a vaccine. Pressures are mounting to get one available for use as soon as possible. 

The pandemic has brought the world to a standstill, and so it is tempting to think that the faster a vaccine is made available the better. 

But it is important to ensure that vaccines are safe — and that they actually work. 

Vaccine hesitancy is widespread and the risk of increasing vaccine hesitancy by rolling out a vaccine without adequate testing is not a risk worth taking. 

READ:Commentary: As Singapore gradually opens its borders, we need to be mindful of a second COVID-19 wave

READ: Commentary: Why is anyone still talking about herd immunity?

The concerning knock-on effects from the vaccine roll-out of the dengue vaccine Dengvaxia in the Philippines should be taken seriously as a mindful example when it comes to the testing and use of COVID-19 vaccines.

Many diseases are vaccine preventable and the road to getting a vaccine developed and available for use is well-trodden and clear. 

LIFECYCLE OF TESTING 

Firstly, there is a pre-clinical phase, followed by three clinical phases of vaccine testing. 

Phase one and two test immunogenicity and safety, and phase three tests efficacy and safety in a larger number of people. 

In phase three trials, there is a vaccinated and un-vaccinated control group. 

These trials aim to determine whether rates of infection are lower in the vaccinated group compared to the unvaccinated.

Normally these trials take 3 to 5 years to complete with a vaccine candidate that is already developed. 

Mexico Flu Vaccine​​​​​​​

But with COVID-19, we have seen development through phase one and two in a matter of months, and vaccines are rapidly moving onto phase three.

So it is perhaps easy to think that the next phase can happen just as quickly. But the length of follow-up in phase three trials is vital and cannot be sped up in quite the same way.

The end of phase two reveals whether a vaccine produces an immune response. 

But just because an immune response is produced, does not mean that a vaccine will protect against infection or disease.

Examples in Russia and China highlight the possibility of widespread use of a vaccination before phase three trials. 

READ: Commentary: Want to travel again? It’s not sitting in a plane you should worry about

READ:Commentary: Dear Indonesia, shaming the infected is a lousy COVID-19 plan

Phase one results have been published for the vaccine developed in China and phase one and two results for the vaccine developed in Russia.

But neither have started phase three trials, though there are now reports of plans for phase three trials in Philippines and mixed reports from Brazil about the possibility of phase three trials there.

DANGERS OF SHORTCUTS

Widespread use of vaccines before phase three trials is problematic for two reasons. 

First, without larger group testing in phase three, there may be safety issues that are yet to be determined. 

A man works in the packaging facility of Chinese vaccine maker Sinovac Biotech, developing an experimental coronavirus disease (COVID-19) vaccine, during a government-organized media tour in Beijing, China, September 24, 2020. REUTERS/Thomas Peter/File Photo

Individuals in phase three trials are closely monitored and there is no guarantee of this happening outside the trial setting. 

A recent example of this process is the stopping and restarting of the trial with the AstraZeneca vaccine in the United Kingdom after a participant had a suspected adverse reaction.

Second, it is impossible to know if a vaccine works without the control group of a phase three trial. 

But even with a good phase three trial, efficacy can only be determined if infection exposures are occurring. 

It has been reported that Vietnam bought large numbers of the Russian vaccine, hopefully to be used in a well-designed phase three trial, however with low transmission here, it may not be possible to determine vaccine efficacy.

It is also important to consider who is included in all phases of trials. In the Chinese example, members of the army, a homogenous group in terms of age and gender, are reported to have been vaccinated. 

READ: Commentary: When will COVID-19 end? History suggests diseases fade but are never truly gone

READ: Commentary: Why the Singapore-Indonesia reciprocal green lane is necessary

This set-up means vital information will be missing on how the vaccine works in certain groups. 

Another reason for collecting excellent efficacy data is the need to compare and choose between multiple vaccines.

WHO GETS IT FIRST? 

This is not to say that we cannot expedite other areas of the process. Once a vaccine has been successful in phase three trials, it needs to be manufactured and available for the people who need it. 

Russia's vaccine was still undergoing trials after its accelerated approval in the country AFP/Natalia KOLESNIKOVA

Building factories to manufacture vaccines at scale before phase three trials are complete will speed up the process, as will building frameworks to make decisions about who will be vaccinated first and how to get vaccines to these groups efficiently.

Every country is currently debating the future of COVID-19 vaccination for their country. 

Many countries have engaged with COVAX, the WHO initiative to ensure global equitable access to vaccines when they become available. 

There are many decisions to be made for each country, and well-designed trials for all vaccines will mean each country can make the necessary decisions to improve the health and wellbeing of their population, with the best possible information available.

Hannah Clapham is Assistant Professor at the Saw Swee Hock School of Public Health, National University of Singapore. This commentary first appeared on East Asia Forum. Read it here.

Source: CNA/an

Advertisement

Also worth reading

Advertisement